Patents Assigned to Takeda
  • Dipeptidyl peptidase inhibitors
    Patent number: 7790734
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: September 7, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Sheldon X. Cao, Jun Feng, Stephen L. Gwaltney, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Xiao-Yi Xiao, Zhiyuan Zhang
  • Dipeptidyl peptidase inhibitors
    Patent number: 7790736
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: September 7, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jun Feng, Stephen L. Gwaltney, II, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
  • Controlled release preparation
    Patent number: 7790755
    Abstract: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: September 7, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yohko Akiyama, Takashi Kurasawa, Hiroto Bando, Naoki Nagahara
  • POLO-LIKE KINASE INHIBITORS
    Publication number: 20100222575
    Abstract: The present invention relates generally to processes of making 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide and Form A of 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide.
    Type: Application
    Filed: September 25, 2008
    Publication date: September 2, 2010
    Applicants: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Christopher McBride, Nie Zhe
  • BENZIMIDAZOLE COMPOUND CRYSTAL
    Publication number: 20100222391
    Abstract: A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
    Type: Application
    Filed: April 30, 2010
    Publication date: September 2, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Akira FUJISHIMA, Isao AOKI, Keiji KAMIYAMA
  • Metastin derivatives and use thereof
    Patent number: 7786083
    Abstract: The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotropic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids, the metastin derivatives of the present invention achieve more improved blood stability, solubility, etc., reduced gelation tendency, improved pharmacokinetics, as well as exhibit an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity. The metastin derivatives of the present invention also have a gonadotropic hormone secretion suppressing activity, sex hormone secretion suppressing activity, etc.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: August 31, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Taiji Asami, Naoki Nishizawa
  • Aminophenylpropanoic acid derivative
    Patent number: 7786165
    Abstract: A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: August 31, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Nobuyuki Negoro, Shinobu Sasaki
  • FUSED HETEROCYCLIC COMPOUND
    Publication number: 20100216788
    Abstract: The present invention provides a compound represented by the formula: wherein R1a is a hydrogen atom, R2a is a C1-6 alkyl group substituted by a group represented by —NR6a—CO—(CH2)n—SO2— optionally halogenated C1-4 alkyl wherein n is an integer of 1 to 4, R6a is a hydrogen atom or a C1-4 alkyl group, and —(CH2)n— is optionally substituted by C1-4 alkyl, R3a is a hydrogen atom or a C1-6 alkyl group, R4a is a halogen atom or a C1-6 alkyl group, R5a is a halogen atom or a C1-6 alkyl group, and Xa is a hydrogen atom or a halogen atom, or a salt thereof. The compound of the present invention has a superior tyrosine kinase inhibitory action, is highly safe, and is sufficiently satisfactory as a pharmaceutical product.
    Type: Application
    Filed: December 1, 2006
    Publication date: August 26, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tomoyasu Ishikawa, Kazuhiro Miwa, Masaki Seto, Hiroshi Banno, Youichi Kawakita
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20100216810
    Abstract: Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Application
    Filed: December 1, 2009
    Publication date: August 26, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masanori OKANIWA, Terufumi TAKAGI
  • KINASE INHIBITORS
    Publication number: 20100216765
    Abstract: Compounds, pharmaceutical compositions and kits are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
    Type: Application
    Filed: April 6, 2010
    Publication date: August 26, 2010
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, David J. Hosfield, Bheema R. Paraselli, Nicholas Scorah, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
  • Method of screening compounds which alter the binding properties of GPR39, and homologs thereof, to bile acid
    Patent number: 7781175
    Abstract: The present invention relates to screening of an agonist/antagonist, etc. Specifically, the present invention provides a method of screening an agonist or antagonist of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or a salt thereof and a cholesterol metabolism-related substance, and so on.
    Type: Grant
    Filed: April 22, 2005
    Date of Patent: August 24, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Ryo Fujii, Kazunori Nishi, Yasuhiro Tanaka, Masaaki Mori
  • Dipeptidyl peptidase inhibitors
    Patent number: 7781584
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising: wherein M is N or CR4; Q1 and Q2 are each independently selected from the group consisting of CO, SO, SO2, and C?NR9; and each L, X, R1, R2, and R3 are as defined herein.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: August 24, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jun Feng, Stephen L. Gwaltney, Jeffrey A. Stafford, Zhiyuan Zhang, Bruce J. Elder, Paul K. Isbester, Grant J. Palmer, Jonathon S. Salsbury, Luckner G. Ulysse
  • RENIN INHIBITORS
    Publication number: 20100210635
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with Renin that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
    Type: Application
    Filed: March 23, 2007
    Publication date: August 19, 2010
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Benjamin Jones, Andre A. Kiryanov, Stephen W. Kaldor
  • 5-MEMBERED HETEROCYCLIC COMPOUND
    Publication number: 20100210696
    Abstract: Provided is a compound having a superior acid secretion suppressive action, which shows an antiulcer activity and the like.
    Type: Application
    Filed: September 24, 2008
    Publication date: August 19, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Haruyuki Nishida, Yasuyoshi Arikawa, Keizo Hirase
  • Indole compound
    Patent number: 7777047
    Abstract: The purpose of the present invention is to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein R1 is a hydrogen atom or a halogen atom; R2 is a group represented by wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: August 17, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Tsuneo Yasuma
  • METHODS OF TREATING HYPERTENSION WITH AT LEAST ONE ANGIOTENSIN II RECEPTOR BLOCKER AND CHLORTHALIDONE
    Publication number: 20100204252
    Abstract: The present invention relates to a method of treating hypertension in a subject or patient needing treatment thereof by administering to said subject or patient at least one angiotensin II receptor blocker in combination with chlorthalidone.
    Type: Application
    Filed: December 22, 2009
    Publication date: August 12, 2010
    Applicant: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
    Inventor: Stuart R. Kupfer
  • MAPK/ERK KINASE INHIBITORS
    Publication number: 20100204471
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
    Type: Application
    Filed: October 22, 2007
    Publication date: August 12, 2010
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Victoria Feher, Stephen W. Kaldor, Naoki Tomita
  • 1,3-benzothiazinone derivatives and use thereof
    Patent number: 7767665
    Abstract: This invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.
    Type: Grant
    Filed: April 8, 2008
    Date of Patent: August 3, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Kajino, Yutaka Nakayama, Akira Kawada, Haruhide Kimura, Taisuke Tawaraishi
  • Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
    Publication number: 20100190763
    Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
    Type: Application
    Filed: January 21, 2010
    Publication date: July 29, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
  • KINASE INHIBITORS
    Publication number: 20100190816
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
    Type: Application
    Filed: February 18, 2010
    Publication date: July 29, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Qing Dong, Bheema R. Paraselli, Nicholas Scorah, Michael B. Wallace, Jeffrey A. Stafford